Non-CNS SE was defined as abrupt vascular insufficiency associated with clinical or radiological evidence of arterial occlusion in the absence of other likely mechanisms. In the presence of atherosclerotic peripheral artery disease (PAD), diagnosis of embolism to the lower extremities required angiographic demonstration of acute arterial occlusion. 4 For patients who met the definition of non-CNS SE, the anatomic location, method of diagnosis, presence of atherosclerosis, and recent trauma or instrumentation of the affected arterial territory were documented. Institutional review board approval was obtained at all sites, and all patients provided written informed consent.
The current analysis is a post hoc subgroup analysis of the intention-to-treat population. Categorical variables are summarized as counts (percentages), and continuous variables are summarized as medians (25th, 75th percentiles) or means (SDs). All analyses were performed with SAS software version 9.2 (SAS Institute, Inc, Cary, NC).
Of 14 264 randomized patients in ROCKET AF, 47 experienced non-CNS SE, corresponding to a rate of 0.183 (95% confidence interval, 0.136-0.241) per 100 patient-years of follow-up. (Patient characteristics are shown in Table. )
Of the 47 non-CNS SE events, 29 occurred in lower extremities, 8 in mesenteric arteries, 6 in upper extremities, 2 in renal arteries, and 1 in the splenic artery; location was not recorded for 1 non-CNS SE.
Methods of diagnosis of non-CNS SE varied, but the most common were ultrasound (34%), computed tomography/angiography (21%), invasive angiography (17%), and magnetic resonance imaging/angiography (2%). Multiple diagnosis methods could be used for a single patient, or patients could be diagnosed clinically. The initial diagnostic test was not standardized or dictated by the study protocol. There were 16 patients in whom no diagnostic test was performed, and although clinical diagnosis was not a prespecified method, this can be inferred.
The use of study medication (rivaroxaban or warfarin) was variable at the time of non-CNS SE. Before the occurrence of non-CNS SE, 21 patients had permanently discontinued study drug, and 2 had temporarily discontinued. Reasons for permanent discontinuation included bleeding adverse events (n=3), nonbleeding adverse events (n=2), noncompliance with study medication (n=1), withdrawn consent (n=5), investigator decision (n=2 [not protocol related]), or the clinical efficacy end point (ie, stroke) was reached (n=8). The median time from permanent discontinuation to non-CNS SE was 24 days (25th, 75th percentiles: 6, 92). However, 168 of the 534 patients who experienced stroke in ROCKET AF permanently stopped study drug before the stroke (31.5%).
After non-CNS SE, 14 patients stopped study medication permanently, 1 temporarily discontinued use, and 7 continued study medication throughout the study. Study medication use was not adequately characterized in 2 patients.
There were 53 interventions in 47 patients; multiple interventions could be attempted in the same patient when clinically indicated. The most common interventions were surgery (47%), medical Systemic Embolism in Patients With Atrial Fibrillation management (28%), and percutaneous intervention (13%); 11% of interventions were not described.
A total of 11 patients died (n=6 rivaroxaban, n=5 warfarin); 7 died within 30 days of non-CNS SE, 2 died between 30 days and 6 months, and 2 died >6 months after the non-CNS SE event. Of the 11 fatal events, 5 occurred in lower extremities, 5 in mesenteric arteries, and 1 in upper extremities.
Among those who survived the non-CNS SE event, 2 patients had a subsequent stroke, 1 required amputation, and 3 experienced major bleeding events. Of those who experienced major bleeding, 1 patient had multiple major bleeding events, and 2 patients had major bleeding on the same day as the non-CNS SE event.
Comment
In patients enrolled in ROCKET AF, non-CNS SE occurred infrequently, at a rate of 0.183 (95% confidence interval, 0.136-0.241) per 100 patient-years. Importantly, non-CNS SE accounted for only 8.2% of the total thromboembolic events, whereas stroke accounted for the remainder, which is similar to previous estimates. 2 The difference in frequency between stroke and non-CNS SE is multifactorial. One explanation for this discrepancy is that the higher prevalence of symptomatic embolization of carotid arteries versus subclavian arteries can be associated with the low resistance and increased volume of blood flow in cerebral arteries. 5 Alternatively, it is reasonable to assume that the disparity is at least partly because of the difficulty in detecting non-CNS events. Cerebral tissue is particularly sensitive to ischemia when compared with other organs. Visceral or mesenteric SE detection is impacted by asymptomatic or nonspecific symptoms, and many of these locations have a rich vascular network leading to collateral circulation and compensation. Consequently, the prevalence of non-CNS SE events likely will remain understated. 5 The vast majority of non-CNS SE events occurred in lower extremity arterial distributions, which is consistent with previous data.
5-7 PAD and previous atherosclerosis in the affected arterial distribution seem to be associated with the occurrence of non-CNS SE, which may suggest that non-CNS SE occurs more readily in areas of diseased vasculature. The mechanism explaining this finding may be that occlusion of the vasculature because of embolic material occurs at areas of atherosclerotic plaque, causing total obstruction of blood flow. 8 Alternatively, some of the association with PAD may be related to thrombosis of a diseased vessel rather than a true embolic event. 5, 8 Bleeding was a major adverse event associated with non-CNS SE (n=3 [6.4%]), and although this sample size is small, the rate of major bleeding seems to be increased compared with the intention-to-treat population (3.6% of patients on rivaroxaban and 3.4% of patients on warfarin). 3 Given the small sample size, it is not possible to draw a conclusion, although patients with non-CNS SE likely received additional procedures and antithrombotic therapy as treatment, thus placing them at increased bleeding risk. There was also 1 patient (2.8%) who required amputation after lower extremity SE (n=35 for all extremity SE). Amputation is required in ≈7% of limb ischemia cases because of PAD. 9 There was a high rate of mortality associated with non-CNS SE, as 11 patients (23.4%) who experienced it died. Significantly, the majority of patients died within 30 days of the event. Even more striking was the difference in mortality based on location of SE. For lower extremity SE, the rate of mortality in ROCKET AF was 17.2%, which is similar to previous reports for acute limb ischemia; previous studies suggest that the mortality rate of acute limb ischemia in the community is ≈9% in hospital and 42.5% at 1 year post-event.
2,10 Visceral SE (including mesenteric, renal, and splenic) has a much higher rate of mortality, with 45.5% of patients experiencing such an event in ROCKET AF eventually dying. This is a representative of previous literature, in which reported mortality rates of visceral or mesenteric ischemia are 55% to 60%. 2 Non-CNS SE is less commonly recognized clinically than ischemic stroke but is associated with significant morbidity and mortality. Although the majority of these events occur in the extremities, visceral events also occur and are associated with high mortality rates. Many patients permanently stopped study medication before non-CNS SE, emphasizing the importance of uninterrupted anticoagulation in patients with AF. There is some suggestion that PAD and previous atherosclerosis may predispose patients to non-CNS SE; additional studies are needed to identify patients at risk and guide appropriate treatment. 
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